- 3 weeks later:
PharMerica beats by $0.02, beats on revs; reaffirms FY16 guidance:
- Reports Q1 (Mar) earnings of $0.45 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.43; revenues rose 2.5% year/year to $524.5 mln vs the $509.45 mln Capital IQ Consensus, adjusted EBITDA was $30.3 mln compared with $35.4 mln year ago.
- Prescriptions dispensed in Q1 were 8.6 mln as compared to 8.4 mln in the fourth quarter of 2015 and 8.2 mln in the third quarter of 2015. This quarter represents the second sequential quarterly increase in prescription volume.
- Co reaffirms guidance for FY16, sees EPS of $1.95-2.05 vs. $2.01 Capital IQ Consensus Estimate; sees FY16 revs of $2.125-2.150 bln vs. $2.13 bln Capital IQ Consensus Estimate, adjusted EBITDA of $130.3 mln to $135.3 mln. "We are confident diversified revenues will exceed $700 mln in 2017, and the diversification program will meaningfully contribute to the Company's overall EBITDA growth over the next several years."
No comments:
Post a Comment